Skip to main content

PRA Health Sciences在2019冠状病毒病（COVID-19）大流行期间通过其移动健康平台扩展远程临床研究支持

Written by Customer Service on . Posted in Public Companies.

北卡罗来纳州罗利市, March 26, 2020 (GLOBE NEWSWIRE) — 为应对全球当前的COVID-19疫情，PRA Health Sciences今天宣布扩大其业界领先的远程临床监测移动健康平台，针对COVID-19虚拟研究支持的申办方需求增加多项新功能。
无论患者身在何处，PRA的移动健康平台都可与其交互。这一基于应用程序的平台让申办方可通过虚拟方式自由使用医生办公室或临床场所。针对COVID-19增加的新功能旨在支持临床试验申办方和参与临床研究的场所，使其能够与因当前疫情流行而无法前往相关地点的患者进行联系和协调。此外，移动应用程序还可将现有的传统纸质研究转变为去中心化程度更高的无地点式研究，从而在关键研究期间让医疗护理和患者评估能够继续进行。移动应用程序为试验人员和临床场所提供了一个管理性的网络应用程序，为患者提供了一个可下载的移动应用程序，从而使临床场所能够：以电子方式同意/再次同意患者使用移动应用程序从患者处收集同意书，允许通过第三方快递机构交付试验药物远程安排并以视频方式进行患者问诊利用移动调查工具为研究人员提供实时意见以确定可行方案“随着COVID-19全球疫情的持续，患者与医生面对面进行问诊或遵守临床研究协议中对前往现场及医院的规定越来越困难。同样具有挑战性和难度的是，相关场所必须能够同时应对试验患者和COVID-19患者的需要。”PRA Health Sciences执行副总裁兼首席科学官Kent Thoelke说。“该移动远程解决方案可以让关键研究得以在协议和监管指南允许的情况下继续进行；而且，在为抗击COVID-19而必须重视社交距离和减轻医疗系统负担之际，这也可以确保患者的安全和健康。”该移动应用程序可以通过患者的手机或平板电脑收集电子知情同意书和电子签名，以及完整的患者报告结果。通过连接设备，该应用程序还可以收集家庭医疗保健数据，并将这些数据用于临床试验。PRA移动健康平台的构建考虑到了各项具体试验的要求，可以在短短一周或更短的时间内快速部署。根据不同的病情、患者人群和申请方目标，PRA的临床技术专家可帮助确定出最适合特定混合实验或分散试验的平台功能。要了解PRA移动健康平台的更多信息，请访问 https://prahs.com/pra-mobile-health-platform.  联系我们的团队： https://prahs.com/contact/virtual。关于PRA HEALTH SCIENCES

 PRA（NASDAQ股票代码: PRAH）是按营收指标全球领先的合同研究机构之一，为生物技术和制药行业提供外包临床开发和数据解决方案服务。PRA全球临床研发平台遍及北美、欧洲、亚洲、拉丁美洲、南非、澳大利亚和中东，共75个办事处，全球员工超过17500人。2000年以来，PRA已参与了世界各地约4000项临床试验。此外，PRA还参与了众多关键性或支持性试验，超过95种产品由此获得了美国食品药品管理局和国际监管机构批准。投资者关系咨询：InvestorRelations@prahs.com媒体咨询：
Laurie Hurst，传播与公共关系总监
HurstLaurie@prahs.com，+1.919.786.8435

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.